Kyverna Therapeutics (Kyverna Therapeutics) Interest Expense : $-0.09 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kyverna Therapeutics's interest expense for the three months ended in Mar. 2024 was $ -0.04 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.09 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kyverna Therapeutics's Operating Income for the three months ended in Mar. 2024 was $ -29.36 Mil. Kyverna Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $ -0.04 Mil. Kyverna Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kyverna Therapeutics Interest Expense Historical Data

The historical data trend for Kyverna Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Interest Expense Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Interest Expense

-0.07

-0.19

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial			-0.04	-0.04	-	-0.05	-0.04

Kyverna Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09 Mil.

Kyverna Therapeutics (NAS:KYTX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kyverna Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $-0.04 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-29.36 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $7.13 Mil.

Kyverna Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Kyverna Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, STE 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024